

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No. 10/755,720
Filing Date January 12, 2004
First Named Inventor Tontonoz, Peter
Art Unit 1617
Examiner Sharareh, Shahnam J.
Attorney Docket No. UCLA019.001A

(Multiple sheets used when necessary)

SHEET 1 OF 1

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear


FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹


NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
MS	1	CHINETTI, G. et al. (2004) "Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPAR α , PPAR γ , and LXR" <i>Biochemical and Biophysical Research Communications</i> 314:151-158.	
	2	HUUSKONEN, J. et al. (2004) "Role of p160 coactivator complex in the activation of liver x receptor" <i>Arterioscler. Thromb. Vasc. Biol.</i> 24:703-708.	
	3	FOWLER, A. et al. (2003) "Liver x receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: liver-x-receptor-specific inhibition of inflammation and primary cytokine production" <i>J. Invest. Dermatol.</i> 120:246-255.	
	4	SVENSSON, S. et al. (2003) "Crystal structure of the heterodimeric complex of LXR α and RXR β ligand-binding domains in a fully agonistic conformation" <i>The EMBO Journal</i> 22:4625-4633.	
MS	5	International Search Report from corresponding PCT application Serial No. PCT/US05/00442.	

2870698:vr082406

Examiner Signature	Date Considered
	01/03/08
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.



FORM PTO-1224 SEP 02 2004 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. UCLA018.001A	APPLICATION NO. 10/755,720
	APPLICANT Tontanoz et al.		
	FILING DATE January 12, 2004	GROUP 1614	


U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS



EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
MAY	1	Callejas, N.A. et al. (2000) "Regulation of cyclooxygenase 2 expression in Hepatocytes by CCAAT/enhancer-binding proteins," <i>Gastroenterology</i> 119:493-501.
	2	Castrillo, A. et al. (2000) "Inhibition of I κ B kinase and I κ B phosphorylation by 15-deoxy- $\Delta^{12,14}$ -prostaglandin J ₂ in activated murine macrophages," <i>Mol. and Cell Biol.</i> 20:1692-1698.
	3	Castrillo, A. et al. (2001) "Inhibition of the nuclear factor κ B (NF- κ B) pathway by tetracyclic kaurene diterpenes in macrophages," <i>J. Bio. Chem.</i> 276:15854-15860.
	4	Chawla, A. et al. (2001) "A PPAR γ -LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis," <i>Mol. Cell</i> 7:161-171.
	5	Chawla, A. et al. (2001) "PPAR- γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation," <i>Nat. Med.</i> 7:48-52.
	6	Chen, L.M. et al. (1996) " <i>Salmonella</i> ssp. are cytotoxic for cultured macrophages," <i>Mol. Microb.</i> 21:1101-1115.
	7	Detmers, P.A. et al. (2000) "Deficiency in inducible nitric oxide synthase results in reduced atherosclerosis in apolipoprotein E-deficient mice," <i>J. Immunol.</i> 165:3430-3435.
	8	Febbraio, M. et al. (2000) "Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice," <i>J. Clin. Invest.</i> 105: 1049-1056.
	9	Fu, X. et al. (2001) "27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells," <i>J. Biol. Chem.</i> 276:38378-38387.
	10	Galis, Z.S. et al. (1995) "Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases," <i>PNAS USA</i> 92:402-406.
	11	Galis, Z.S. et al. (2002) "Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling," <i>Circ. Res.</i> 91:852-859.
MM	12	Glass, C.K. et al. (2001) "Atherosclerosis: the road ahead," <i>Cell</i> 104:503-516.

EXAMINER		DATE CONSIDERED	02/03/02
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. UCLA019.001A	APPLICATION NO. 10/755,720
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT Tontono et al.	
	FILING DATE January 12, 2004	GROUP 1614



EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	13	Gu, L. et al. (1998) "Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice," <i>Mol. Cell</i> 2:275-281.
	14	Hansson, G.K. (1999) "Inflammation and immune response in atherosclerosis," <i>Curr. Atheroscler. Rep.</i> 1:150-155.
	15	Herrlich, P. (2001) "Cross-talk between glucocorticoid receptor and AP-1," <i>Oncogene</i> 20:2465-2475.
	16	Jiang, C. et al. (1998) "PPAR- γ agonists inhibit production of monocyte inflammatory cytokines," <i>Nature</i> 391:82-86.
	17	Joseph, S.B. et al. (2002) "Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors," <i>J. Biol. Chem.</i> 277:11019-11025.
	18	Joseph, S.B. et al. (2002) "Synthetic LXR ligand inhibits the development of atherosclerosis in mice," <i>PNAS USA</i> 99:7604-7609.
	19	Joseph, S.B. et al. (2003) "Reciprocal regulation of inflammation and lipid metabolism by liver X receptors," <i>Nature Med.</i> 9:213-219.
	20	Karin, M. et al. (2001) "AP-1-glucocorticoid receptor crosstalk taken to a higher level," <i>J. Endocrinol.</i> 169:447-451.
	21	Kuhlencordt, P.J. (2001) "Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice," <i>Circulation</i> 103:3099-3104.
	22	Lafitte, B.A. et al. (2001) "Autoregulation of the human liver X receptor α promoter," <i>Mol. Cell. Biol.</i> 21:7558-7568.
	23	Lafitte, B.A. et al. (2002) "Orphan Nuclear Receptors find a home in the arterial wall," <i>Curr. Atheroscler. Rep.</i> 4:213-221.
	24	Li M. et al. (2000) "Peroxisome proliferator-activated receptor γ -dependent repression of the inducible nitric oxide synthase gene," <i>Mol. & Cell. Bio.</i> 20:4699-4707.
	25	Liu, S-X. et al. (1998) "Oxidized cholesterol in oxidized low density lipoprotein may be responsible for the inhibition of LPS-induced nitric oxide production in macrophages," <i>Atherosclerosis</i> 136:43-49.
	26	Lowenstein, C.J. (1993) "Macrophage nitric oxide synthase gene: two upstream regions mediate induction by interferon γ and lipopolysaccharide," <i>PNAS USA</i> 90:9730-9734.
	27	Lusis, A.J. (2000) "Atherosclerosis," <i>Nature</i> 407:233-241.
	28	Mestre, J.R. et al. (2001) "Redundancy in the signaling pathways and promoter elements regulating cyclooxygenase-2 gene expression in endotoxin-treated macrophage/monocytic cells," <i>J. Biol. Chem.</i> 276:3977-3982.
	29	Moore, K.J. et al. (2001) "The role of PPAR- γ in macrophage differentiation and cholesterol uptake," <i>Nat. Med.</i> 7:41-47.
	30	Nagy, L. et al. (1998) "Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR γ ," <i>Cell</i> 93:229-240.
	31	Nissen, R.M. et al. (2000) "The glucocorticoid receptor inhibits NF κ B by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain," <i>Gen. & Dev.</i> 14:2314-2329.
	32	Pasterkamp, G. et al. (2000) "Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteinases 1, 2 and 9 in the human coronary artery," <i>Atherosclerosis</i> 150:245-253.
	33	Repa, J.J. et al. (2000) "The role of orphan nuclear receptors in the regulation of cholesterol homeostasis," <i>Annu. Rev. Cell Dev. Bio.</i> 16:459-481.
	34	Repa, J.J. et al. (2002) "The liver X receptor gene team: potential new players in atherosclerosis," <i>Nat. Med.</i> 8:1243-1248.
	35	Ricote, M. et al. (1998) "The peroxisome proliferator-activated receptor- γ is a negative regulator of macrophage activation," <i>Nature</i> 391:79-81.

EXAMINER 	DATE CONSIDERED 
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. UCLA019.001A	APPLICATION NO. 10/755,720
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT Tontonoz et al.	
	FILING DATE January 12, 2004	GROUP 1614

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	36	Sheu, M.Y. et al. (2002) "Topical peroxisome proliferator activated receptor- α activators reduce inflammation in irritant and allergic contact dermatitis models," <i>J. Invest. Dermatol.</i> 118:94-101.
	37	Straus, D.S. et al. (2000) "15-Deoxy- $\Delta^{12,14}$ -prostaglandin J ₂ inhibits multiple steps in the NF-kB signaling pathway." <i>PNAS USA</i> 97:4844-4849.
	38	Suzuki, H. et al. (1997) "A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection." <i>Nature</i> 386:292-295.
	39	Tangirala, R.K. et al. (2002) "Identification of macrophage liver X receptors as inhibitors in atherosclerosis." <i>PNAS USA</i> 99:11896-11901.
	40	Tontonoz, P. et al. (1998) "PPAR γ promotes Monocyte/Macrophage differentiation and uptake of oxidized LDL." <i>Cell</i> 93:241-252.
	41	Wu, Z.L. et al. (1997) Oxidized low-density lipoprotein decreases the induced nitric oxide synthesis in rat mesangial cells." <i>Cell Bio. & Function</i> 16:153-158.

O:\DOCS\MXG\MXG-5821.DOC:vr
082504

EXAMINER 	DATE CONSIDERED 
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	